# US 2020/0399396 A1 · Anti-tip-1 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399396 A1
- Document ID: US20200399396A1
- Status: Published application
- Kind: A1
- Application number: 15/733,554
- Filed: 2019-03-06
- Published: 2020-12-24
- Earliest claimed: 2018-03-08
- Assignees: Phanes Therapeutics, Inc.
- Applicants: Phanes Therapeutics, Inc.
- Inventors: Minghan Wang; Hui Zou; Joshua Oaks
- Web page: https://patentgrep.com/patent/US20200399396A1

## CPC

- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/31: multispecific
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Anti-TIP-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

## Claims

### Claim 1

An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequence of:
a. SEQ ID NOs:3, 4, 5, 6, 7, and 8, respectively;
wherein the antibody or antigen-binding fragment thereof specifically binds TIP 1.

### Claim 2 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO:1, or a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO:2.

### Claim 3 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising:
a. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:1, and a light chain variable region having the polypeptide sequence of SEQ ID NO:2.

### Claim 4 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is capable of inducing effector-mediated tumor cell lysis.

### Claim 5 (depends on 1)

The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof is chimeric or human or humanized.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

An isolated nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof of claim 1.

### Claim 8 (depends on 7)

A vector comprising the isolated nucleic acid of claim 7.

### Claim 9 (depends on 8)

A host cell comprising the vector of claim 8.

### Claim 10 (depends on 1)

A pharmaceutical composition, comprising the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

A method of treating cancer or targeting TIP-1 on a cancer cell surface in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 10.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method of producing the monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising culturing a cell comprising a nucleic acid encoding the monoclonal antibody or antigen-binding fragment thereof under conditions to produce the monoclonal antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the cell or culture.

### Claim 14 (depends on 1)

A method of producing a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment of claim 1, comprising combining the monoclonal antibody or antigen-binding fragment thereof with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

### Claim 15 (depends on 1)

A method of determining a level of TIP-1 in a subject, the method comprising:
a. obtaining a sample from the subject;
b. contacting the sample with an isolated monoclonal antibody or antigen-binding fragment thereof of claim 1; and
c. determining a level of TIP-1 in the subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the sample is a tissue sample or a blood sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tissue sample is a cancer tissue sample.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

An isolated bispecific antibody or antigen-binding fragment thereof comprising the monoclonal antibody or antigen-binding fragment thereof of claim 1.

### Claim 20 (depends on 19)

An isolated nucleic acid encoding the bispecific antibody or antigen-binding fragment thereof of claim 19.

### Claim 21 (depends on 20)

A vector comprising the isolated nucleic acid of claim 20.

### Claim 22 (depends on 21)

A host cell comprising the vector of claim 21.

### Claim 23 (depends on 19)

A pharmaceutical composition comprising the isolated bispecific antibody or antigen-binding fragment thereof of claim 19 and a pharmaceutically acceptable carrier.